NASDAQ | VICL: 1.29  +0.04
investors
Investors

News Releases

DateSubject
August 23, 2018 Vical to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 7, 2018 Vical Reports Second Quarter 2018 Financial and Operational Results
July 19, 2018 Vical Announces Review of Potential Strategic Transactions
June 11, 2018 Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint
May 3, 2018 Vical Reports First Quarter 2018 Financial and Operational Results
April 26, 2018 Vical Announces News Release and Conference Call Schedule for First Quarter 2018 Financial Results
March 15, 2018 Vical Reports Fourth Quarter 2017 Financial and Operational Results
March 8, 2018 Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial Results
February 20, 2018 Vical Initiates Phase 2 Trial of VL-2397 Antifungal for Invasive Aspergillosis
February 1, 2018 Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal VL-2397 for the Treatment of Invasive Aspergillosis
January 30, 2018 Vical Announces Restructuring to Focus Resources on HSV-2 and Antifungal Clinical Programs
January 22, 2018 Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.